Analgesic Effects of a Treatment With Cannabis Sativa Extract in Patients With Knee Osteoarthritis - CANOA (Cannabis for Osteoarthritis)
Key facts
- Who runs it
- Federal University of Latin American Integration
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 45 people enrolled
- Started
- 1 Jan 2024
- Ended
- 12 Oct 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Medium Chain Triglyceride solution
- Cannabis Sativa
- Record updated
- 2 July 2025
Who can take part
- Age
- 30 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (13)Hide the full registry criteria
Who can take part
- Have a diagnosis of knee osteoarthritis, according to the ACR classification criteria (ALTMAN, 1986)
- Have a moderate or high level of pain induced by osteoarthritis (visual analog scale scale equal to or greater than 5)
- Voluntarily agree to take part in the study by signing the Informed Consent Form (ICF)
- For women of reproductive age, a negative Beta-HCG test, and use of a contraceptive method throughout the study
- For women of reproductive age, a negative Beta-HCG test, and use of a contraceptive method throughout the study and 3 months after its conclusion
- Age range of thirty (30) to seventy (70) years
Who cannot take part
- People with heart failure, hypertension or any heart disease
- People with chronic kidney disease or liver failure
- Patients with chronic inflammatory diseases
- Patients with severe psychiatric illnesses, such as severe mood disorders and psychotic disorders
- Current use of cannabinoids by any route of administration
- Pregnant women
- Lactating women
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Osteoarthritis (OA) is the most prevalent joint disease in humans, often causing disability in affected individuals, especially the elderly. OA is characterized by mechanical joint pain, crepitus and short-term post-immobilization stiffness. OA pain has a variable pathophysiology and, despite the many pharmacological options available, its treatment is often ineffective and has significant side effects. The search for more effective and safer treatments is therefore essential in the field of OA. Among the possible treatments are substances derived from cannabis. Cannabis plants have been used for various purposes by humankind for thousands of years. Its best-known species, Cannabis sativa, has more than a hundred substances called cannabinoids or, more specifically, phytocannabinoids, the most important of which is cannabidiol (CBD). Although many pre-clinical studies indicate the usefulness of phytocannabinoids, clinical evidence for their application is currently scarce. Therefore, this project aims to investigate the effects of a CBD-rich extract of Cannabis sativa on the pain of patients with knee OA, as well as the possible adverse events of this treatment.
The 2 groups in the trial
- Group 1Placebo, for comparison
placebo (solution of Medium Chain Triglycerides, without any active ingredient)
Treatment: Medium Chain Triglyceride solution
- Group 2Treatment being tested
Cannabis sativa extract with a CBD (45 mg/day)
Treatment: Cannabis Sativa
Results explained
A paper that names this trial, explained in plain words.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 2 July 2025